Calibrating microglia states in Alzheimer’s disease: decoding immune-metabolic networks and nano-targeted multicomponent therapies
By
Jin Feng Xing
Kaijin Mu
Xue Yan
Xu Yang
Dongnan Zhang
Wanning Gao
Tengyue Zhang
Shuangying Yang
Runze Wang
Weimin Zhang
Yilong Zhu
June 16, 2026
Clinical Scorecard: Adjusting Microglial States in Alzheimer’s Disease: Unraveling Immune-Metabolic Interactions and Targeted Multicomponent Therapeutic Approaches
At a Glance
Category Detail
Condition Key Mechanisms Microglial dysfunction driven by TREM2–APOE axis, complement-mediated synaptic elimination, and immunometabolic reprogramming. Target Population Care Setting
Key Highlights
Anti-Aβ monoclonal antibodies show modest cognitive improvement but significant disease-modifying effects. Microglia play a central role in Alzheimer's disease susceptibility and progression. Current therapies must address both pathology removal and microenvironment protection. Microglial states are dynamic and influenced by genetic, sex, and environmental factors. Guideline-Based Recommendations
Diagnosis
Utilize genomic studies to identify late-onset AD risk genes. Management
Incorporate microglial state calibration in therapeutic approaches. Monitoring & Follow-up
Carefully monitor for amyloid-related imaging abnormalities in patients receiving anti-Aβ therapies. Risks
Adverse events associated with amyloid clearance therapies include amyloid-related imaging abnormalities. Patient & Prescribing Data
Patients with early symptomatic Alzheimer's disease.
Therapies should be tailored based on disease stage, genetic profile, and microglial state-associated biomarkers.
Clinical Best Practices
Shift from single-target approaches to multicomponent therapeutic strategies. Related Resources & Content
